FDA's New Rules for Cheaper Copycat Drugs: Biosimilars Get a Guidance Boost
Published Date: 9/9/2025
Notice
Summary
The FDA just released final advice to help drug makers prove their new protein medicines are just as good as the originals. This update affects companies developing biosimilars by clarifying how to compare products and what info to include in their applications. It aims to speed up approval and save money by making the process clearer and more reliable.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Clarifies how to show biosimilarity
The FDA released final guidance explaining how drug makers should design and evaluate comparative analytical studies to show a therapeutic protein is biosimilar to a reference product licensed under the Public Health Service Act. The guidance finalizes and replaces the draft guidance issued May 22, 2019 and the prior final guidance issued April 30, 2015.
Specifies CMC info for biosimilar applications
The final guidance provides recommendations to sponsors on the scientific and technical information to include in the chemistry, manufacturing, and controls (CMC) section of a marketing application submitted under the Public Health Service Act. Sponsors developing therapeutic protein biosimilars should follow these CMC recommendations when preparing their applications.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-17222 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tobacco Product Establishment Registration and Listing
The FDA wants to keep track of tobacco product makers by updating their registration and listing rules. This affects businesses that make or sell tobacco products, who’ll need to share info with the FDA. The government is checking the paperwork to make sure it’s fair and won’t cost too much time or money.
Next: 2025-17228 — Cheniere Corpus Christi Pipeline, LP; Notice of Request for Extension of Time
Cheniere Corpus Christi Pipeline, LP is asking for more time—until the end of 2029—to finish building their Stage 3 Pipeline Project in Texas. This project includes a big pipeline and some powerful compressor machines to help move gas. The delay means they need extra time to complete important parts, but they’ve already started and even put some equipment to work.